Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.28M | -72.12M | -75.40M | -80.44M | -86.62M |
| Total Depreciation and Amortization | 3.33M | 3.29M | 3.17M | 3.11M | 3.12M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.99M | 12.54M | 12.09M | 14.59M | 15.36M |
| Change in Net Operating Assets | -32.14M | -32.06M | -30.36M | -32.30M | -32.27M |
| Cash from Operations | -86.10M | -88.35M | -90.49M | -95.03M | -100.41M |
| Capital Expenditure | -50.00K | -529.00K | -838.00K | -833.00K | -906.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.09M | 121.63M | 25.05M | -26.77M | -29.00M |
| Cash from Investing | 112.04M | 121.10M | 24.21M | -27.60M | -29.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.02M | 446.00K | 1.84M | 104.99M | 106.01M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -390.00K | -585.00K | -585.00K |
| Cash from Financing | 1.02M | 446.00K | 1.45M | 104.40M | 105.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.96M | 33.20M | -64.83M | -18.23M | -24.88M |